tradmap

BDTX Black Diamond Therapeutics, Inc.

$1.65 -0.90%

Healthcare · Biological Products, (No Diagnostic Substances)

Black Diamond Therapeutics, Inc. (BDTX) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $95 million. Shares last traded at $1.65, 66.6% below their 52-week high. Over the past year the stock is down 28.7%. BDTX trades at a price-to-earnings ratio of 0.00, below the Biological Products, (No Diagnostic Substances) median of 22.74. Net profit margin is 31952.9%, above the peer median of 6.3%.

Market Cap
$95M
Shares Out
57.3M
EPS (TTM)
$2.27
P/E Ratio
0.73
P/S Ratio
1.35
P/B Ratio
0.91
Dividend / Share
Dividend Yield
52-Week High
$4.94
52-Week Low
$1.62
Volume
115,659
Avg Vol (3m)
82,206.778

Performance

1W
-9.84%
1M
-45.00%
3M
-23.61%
6M
-37.38%
YTD
-34.13%
1Y
-28.73%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
30.03
SMA (50)
$2.54
SMA (200)
$2.88
Price vs SMA50
-35.09%
Price vs SMA200
-42.70%
ATR (14)
$0.19

Financials

Revenue
$70M
Net Income
$22.4B
Gross Margin
Operating Margin
17.9%
Net Margin
31952.9%
Return on Equity
21444.9%
Return on Assets
16827.2%
Current Ratio
8.46
Debt / Equity
0.27
Revenue Growth (YoY)

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.16 2026-05-07
FY 2025 $0.39 2026-03-16
Q3 2025 $0.65 2025-11-06
Q2 2025 $0.80 2025-08-07
Q1 2026 $0.98 2026-05-07
FY 2025 $-1.27 2026-03-16

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

BDTX vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/E vs peers
0.00 / 22.74 med
-100% discount
P/S vs peers
1.35 / 5.21 med
-74% discount
Net margin vs peers
31952.9% / 6.3% med
above median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.